<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00520585</url>
  </required_header>
  <id_info>
    <org_study_id>CS-15-11-2006</org_study_id>
    <nct_id>NCT00520585</nct_id>
  </id_info>
  <brief_title>Study of Influence of Atorvastatin on the Repolarisation Phase of Cardiomyocytes</brief_title>
  <acronym>ATORVA</acronym>
  <official_title>Study of Influence of Atorvastatin on the Repolarisation Phase of Cardiomyocytes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masaryk University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masaryk University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate influence of atorvastin on the repolarisation phase of
      cardiomyocytes. If there is any, it could be a part of positive &quot;non-lipid&quot; effect of statins
      in therapy of ischaemic heart disease.

      Study hypothesis: atorvastin will decrease heterogeneity of repolarisation of cardiomyocytes
      in comparison with placebo
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The group will consist of 40 healthy volunteers. The study will be mono-centric. The
      repolarisation phase of cardiomyocytes will be evaluated using long - term 12-lead digital
      ECG monitoring. There will be 3 single ECG recordings - randomly after 20 mg of atorvastin,
      80 mg of atorvastatin and placebo, respectively.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2007</start_date>
  <completion_date type="Anticipated">November 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <condition>Heterogeneity of Cardiomyocytes Repolarisation</condition>
  <condition>Autonomic Changes of Cardiomyocytes Repolarisation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin</intervention_name>
    <description>atorvastatin 20 mg once vs. atorvastatin 80 mg once vs. placebo</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  signed informed consent

          -  age 18 - 45 years

        Exclusion Criteria:

          -  no chronic active disease

          -  no concomitant pharmacotherapy, excluding hormonal contraception

          -  abnormal ECG, echocardiography, laboratory findings

          -  known hypersensitivity or myopathy due o statin

          -  pregnancy, lactation, breast implants

          -  skin disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ondrej Toman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Brno, Department of Cardiology, Brno, Czech Republic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ondrej Toman, MD</last_name>
    <phone>+420532232651</phone>
    <email>ondrej.toman@atlas.cz</email>
  </overall_contact>
  <verification_date>August 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2007</study_first_submitted>
  <study_first_submitted_qc>August 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2007</study_first_posted>
  <last_update_submitted>August 22, 2007</last_update_submitted>
  <last_update_submitted_qc>August 22, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2007</last_update_posted>
  <keyword>atorvastatin</keyword>
  <keyword>repolarisation</keyword>
  <keyword>cardiomyocytes</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

